Pune-based drug maker Brinton Pharmaceutical on Friday said it plans to invest i .
Brinton Pharma yesterday announced a tie-up with Scholl Wellness for the sales and distribution of the latter’s products in the Indian market, Brinton Pharma informed in a statement.
Brinton Pharmaceutical announced that the company will launch the Drug Controller General of India (DCGI) approved molnupiravir (brand name ‘Molviton’) for emergency use in the country for the treatment of SARS-Cov-2.
Leading pharma company Brinton has launched a wellness and personal care range named “Hohner Health”. Hohner has a wide range of products in nutritional supplements, baby skincare and personal care categories.
Brinton Pharmaceuticals has received approval from Drugs Controller General of India (DCGI) for the launch of Favipiravir 400mg under the brand name Faviton. Under the current treatment regimen with favipiravir 200 mg tablets, patients have to take 18 tablets on day one and followed by eight tablets for the next 10-14 days.